Profile picture
, 4 tweets, 4 min read
My Authors
Read all threads
NEW Research—No evidence of benefit for #chloroquine and #hydroxychloroquine in #COVID19 patients, urgent randomised trials are needed: finding from a large observational study of nearly 15,000 patients with #COVID19 & 81,000 controls hubs.ly/H0qMlXr0

Thread (1/4)
Study finds use of chloroquine or #hydroxychloroquine with or without a macrolide is linked to increased rates of mortality and heart arrhythmias among hospital patients with #COVID19 (2/4)
Authors suggest that these drug regimens should not be used to treat #COVID19 outside of clinical trials and urgent confirmation from randomised clinical trials is needed (3/4)
“The findings...add to preliminary reports suggesting that regimens of chloroquine or #hydroxychloroquine, alone or with azithromycin, are not useful & could be harmful in hospitalised patients with #COVID19” - Comment from C Funck-Brentano & J Salem hubs.ly/H0qMj2j0 (4/4)
Missing some Tweet in this thread? You can try to force a refresh.

Enjoying this thread?

Keep Current with The Lancet

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Related hashtags

#chloroquine #hydroxychloroquine #COVID19

More from @TheLancet see all

Profile picture
The Lancet
@TheLancet
NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial hubs.ly/H0qMrl-0

Thread (1/3)
Vaccine candidate was well tolerated at all doses with no serious adverse events reported within 28 days. Most adverse events were mild or moderate; 83% of those receiving low & middle doses & 75% in the high dose group reporting at least 1 adverse reaction within 7 days (2/3)
Study of 108 adults finds vaccine produced neutralising antibodies and T-cell response against SARS-CoV-2, but further research is needed to confirm whether the vaccine protects against #SARSCoV2 infection (3/3)
Read 3 tweets
Profile picture
The Lancet
@TheLancet
NEW Research—First randomised trial of #remdesivir for hospitalised patients who are critically ill with #COVID19 suggests antiviral drug is not associated with significant clinical benefits vs placebo: study of 237 adults from 10 hospitals in Wuhan (1/5) hubs.ly/H0p-BMJ0
Authors note that the study was stopped early by the data safety monitoring board because of difficulty recruiting patients after the #COVID19 outbreak in Wuhan, China was brought under control & more research is needed (2/5)
While not statistically significant, pre-specified secondary outcomes found that time to clinical improvement & duration of invasive mechanical ventilation were shorter in people treated with remdesiver within 10 days of showing symptoms, compared with standard care (3/5)
Read 6 tweets
Profile picture
The Lancet
@TheLancet
NEW #COVID19—First study identifies risk factors associated with death in adults hospitalised with new #coronavirus disease in 2 hospitals in Wuhan, China hubs.ly/H0nsfmD0
Specifically, being of an older age, having a high Sequential Organ Failure Assessment (SOFA) score & having d-dimer greater than 1 μg/L are the factors that could help clinicians to identify #COVID19 patients with poor prognosis at an early stage
Study also suggests #COVID19 hospitalised patients shed the virus for longer than expected—median duration of viral shedding was 20 days in survivors & virus was detectable until death in the 54 non-survivors, but true duration of viral shedding for all patients remains unclear
Read 12 tweets

Embed code for your website

×
Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!